CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg given once weekly. Unlike the other blends in this category it has been through phase 3 and published in the New England Journal of Medicine; it is not yet approved.

Check the amounts on the vial rather than assuming them from the blend name.

Potential. Review the research and limitations before relying on this record.

Two complementary satiety pathways rather than one reinforced. Semaglutide is a GLP-1 receptor agonist acting on glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling; cagrilintide is a long-acting amylin analogue acting on calcitonin and amylin receptors in the hindbrain to promote satiation. Amylin and GLP-1 are distinct hormones with distinct receptors, which is why the combination was developed rather than a higher dose of either.

Both components were engineered for once-weekly subcutaneous dosing - semaglutide by fatty-diacid albumin binding and DPP-4-resistant substitution, cagrilintide by acylation - so unlike the vendor blends the two halves of this vial are cleared on deliberately matched timescales. A phase 1b study characterised the two given together before the phase 3 programme began.

REDEFINE 1 was a 68-week double-blind phase 3 trial in 3,417 adults with obesity or overweight and at least one comorbidity, without type 2 diabetes, randomised to CagriSema, semaglutide alone, cagrilintide alone or placebo. Mean weight change was -20.4% against -3.0% for placebo on the treatment-policy estimand, and 22.7% on the trial-product estimand; semaglutide alone reached 16.1% and cagrilintide alone 11.8%, so the combination beat both monocomponents. REDEFINE 2 covered adults with type 2 diabetes. An important qualifier sits in the dosing: only 57.3% of CagriSema participants were on the highest dose at 68 weeks, against 82.5% for cagrilintide and 70.2% for semaglutide, and the trial fell short of the 25% figure the sponsor had signalled.

The most common adverse events were gastrointestinal, mostly mild to moderate and diminishing over time, consistent with the GLP-1 class. A REDEFINE 1 analysis published in Hypertension reported reduced blood pressure. There is no approved label yet, so there is no regulator-verified adverse-reaction table - the safety picture is trial-reported rather than label-verified, and the class warnings that apply to semaglutide have not yet been formally extended to this combination.

This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.